Sanofi Oncology

Sanofi Oncology is a global leader in the research and development of innovative cancer therapies. The division focuses on a diverse range of cancer types and stages, employing extensive expertise to address the varying needs of patients. Sanofi's oncology portfolio includes treatments for conditions such as metastatic cutaneous squamous cell carcinoma and various hematologic malignancies, among others. The company is committed to advancing cancer treatment through drug discovery, translational research, and preclinical studies, utilizing cutting-edge methodologies in signal transduction and molecular receptor chemistry. With a strong emphasis on patient-centric solutions, Sanofi Oncology aims to create long-term value by delivering effective therapies tailored to the complexities of cancer care.

Alba Zurriaga Carda

Director of Digital Investments at Sanofi Ventures

Jean-Baptiste Chasseloup de Chatillon

Executive Vice President and CFO

Paul Hudson

CEO

Franqui Jimenez

Business Partner Rare Disease Cluster, Global MSAT

Jiuyi Lu

Associate Director in Cell Culture Development

Lydia Mikhaylyants

Associate Director, Global Market Access-Strategic Pricing, Rare Disease and Rare Blood Disorders

John O'Malley

Principal Clinical Research Director and Global Clinical Lead, Amlitelimab

Gustavo Pesquin

Senior Vice President North America, General Medicines BU

Past deals in Lyon

Novadiscovery

Series A in 2021
Novadiscovery SAS, established in 2010 and located in Lyon, France, specializes in the development of Jinko, an in silico clinical trial simulation platform. This innovative platform assists pharmaceutical and biotechnology companies in conducting virtual trials, allowing them to predict the clinical benefits of new drugs prior to human testing. Jinko focuses on various therapeutic areas, including immuno-oncology, orphan diseases, metabolic diseases, and cardiotherapy. By utilizing advanced mathematics and intelligent algorithms, Novadiscovery creates a community of virtual patients, enabling researchers to optimize drug discovery processes, reduce risks, and minimize costs associated with bringing new drugs to market.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.